SCHEMBL220072

SCHEMBL220072

Cc1cc(C(=O)O)n[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28875184 0.84 HCAR2 (0.72)
SCHEMBL2629428 0.82
SCHEMBL4420054 0.80
SCHEMBL3760634 0.80
SCHEMBL2629429 0.80
SCHEMBL3954952 0.77 HCAR2 (1.00)
SCHEMBL2619220 0.77 DAO (0.62)
SCHEMBL3624738 0.77 MAPK1 (0.67)
SCHEMBL15218944 0.77 HCAR2 (0.62)
SCHEMBL8025187 0.77 HCAR2 (0.62)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 634 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-12-09 US claimed
CN-110167944-B Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors 联合疗法公司 2024-08-23 CN claimed
EP-3601284-B1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 HOFFMANN LA ROCHE (CH) 2023-12-27 EP claimed
US-20230263772-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION NEUMENTUM INC (US) 2023-08-24 US claimed
EP-4136072-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION Neumentum, Inc. (US) 2023-02-22 EP claimed
CN-113993846-A Compositions and methods for treating pain and/or inflammation 诺门图姆股份有限公司 2022-01-28 CN claimed
US-20220008390-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION NEUMENTUM, INC. 2022-01-13 US claimed
WO-2021211681-A1 COMPOSITIONS AND METHODS FOR TREATING PAIN AND/OR INFLAMMATION NEUMENTUM, INC. (US) 2021-10-21 WO claimed
EP-2988321-B1 CLEANING LIQUID COMPOSITION KANTO KAGAKU (JP) 2019-03-20 EP claimed
US-20190070149-A1 PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2019-03-07 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed
WO-2006108489-A1 AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-10-19 WO claimed
WO-2005084663-A1 HETERO-SUBSTITUTED ACETANILIDE DERIVATES AS ANALGESIC AGENTS JANSSEN PHARMACEUTICA N.V. (US) 2005-09-15 WO claimed
US-20050182108-A1 or antipyretics; use of N-heterocyclecarboxylic acid, p-hydroxyphenyl amides or N-(p-hydroxyphenyl)-2-thio-group substituted acetamides; e.g. Pyrrolidine-2-carboxylic acid (p-hydroxyphenyl)-amide; substitute for aspirin in upper GI disease, aspirin allergy, bleeding disorders, clients on anticoagulants JANSSEN PHARMACEUTICA, N.V. (BE) 2005-08-18 US claimed
US-20050171346-A1 Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation AVENTIS PHARMA S.A. (FR) 2005-08-04 US claimed
US-20050080260-A1 Preparation of prodrugs for selective drug delivery LUMINIDE 2005-04-14 US claimed
US-20050004178-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2005-01-06 US claimed
US-20040142377-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2004-07-22 US claimed
US-20040097482-A1 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications SCHERING CORPORATION 2004-05-20 US claimed
EP-0749448-B1 USE OF PYRAZOLE-BLOCKED POLYISOCYANATES IN ONE-COMPONENT CLEAR COATINGS ARCO CHEM TECH (US) 2001-05-30 EP claimed